Voloshin et al. demonstrated that TTfields lead to immune activation both in vitro and in vivo and that combining TTfields to PD-L1 leads to significantly greater tumor volume reduction than either treatment alone in lung and colon cancer murine models [50]. This evidence concerns the gene CD274 and malignant colon neoplasm.